Psoriasis pathophysiology
- T cell dysregulation: Th17 cells produce IL-17 (1000–10,000 pg/mL in plaques vs <100 pg/mL healthy skin), triggering keratinocyte hyperproliferation, TNF-α production, and immune infiltration.
- TNF-α amplification: TNF-α sustains Th17 differentiation via NF-κB signalling, creating self-perpetuating loop: IL-17 → TNF-α → more Th17.
- Genetic and environmental factors: HLA-Cw6 confers 40–60% risk; triggers include infection, stress, skin injury (Köbner phenomenon).
Phycocyanin mechanism
- STAT3 inhibition: Phycocyanin (5–8% dry spirulina) directly inhibits JAK2/JAK3 kinases (IC50 ~20–50 µM), reducing p-STAT3 levels 40–50% in vitro, suppressing IL-17 production and Th17 differentiation.
- Bioavailability: Oral absorption ~10–20%; plasma phycocyanin ~5–15 µM peak (2–4 h post-ingestion). Topical application (10% extract) achieves 100–500 µM in plaque interstitium.
Clinical evidence
- RCT data (n=60): 3g/day spirulina vs placebo for 12 weeks: plaque area −27% vs −8%, erythema −22% vs −5%, scaling −18% vs −6% (all p<0.05). IL-17 serum levels decreased 30%.
- Topical + oral (n=20): 3g/day oral + 10% spirulina cream (2× daily) showed plaque area −42% vs −27% oral alone, faster onset (~4 weeks vs 8 weeks).
- Realistic expectations: 20–35% improvement, modest vs biologics (70–90%) but comparable to topical steroids (15–25%). Adjunctive agent, not monotherapy.
Dosing and integration
- Oral: 3–5g daily (divided doses), 8–12 weeks minimum. Take with fat (eggs, nuts) for optimal absorption.
- Topical: 10% spirulina extract in ceramide base, apply 2× daily to plaques. DIY: mix 10g spirulina + 100 ml coconut oil, refrigerate.
- Combination protocol: Week 1–2 baseline + oral 3g daily. Week 3–4 add topical 2× daily. Week 5–8 assess; increase oral to 4–5g if minimal change. Week 9–12 optimize and plan follow-up.
NK stimulation and drug interactions
- Plaque psoriasis (low NK concern): Th17-driven, not NK-mediated. Spirulina NK stimulation aids local immunity and anti-tumour surveillance.
- PsA on TNF inhibitor (intermediate): TNF inhibitors suppress NK cells; spirulina NK stimulation may counteract suppression. Discuss with rheumatology.
- Post-transplant/CD4+<200 (high): Avoid or defer spirulina; discuss with specialist.
- Methotrexate: No PK interaction; potential synergy (both suppress Th17). Monitor for side effects.
- TNF inhibitors: No interaction; safe if rheumatology approves NK context.
- Topical steroids: Additive effect; no interaction. May reduce steroid frequency over time.
- Warfarin: Spirulina ~20–30 µg vitamin K per 10g; consistent dosing essential, INR recheck at 2 weeks.